1. Topic: AS08-Treatment/AS08g-Clinical trials - Phase II-III: EFFICACY OF CPX-351 AS FIRST LINE TREATMENT FOR HIGHER RISK (HR) MDS/CMML. A STUDY BY THE GFM. (September 2021) Authors: Peterlin, P.; Turlure, P.; Chevallier, P.; Gourin, M.-P.; Dumas, P.-Y.; Thepot, S.; Berceanu, A.; Park, S.; Hospital, M.-A.; Cluzeau, T.; Torregrossa-Diaz, J.-M.; Devron, L.; Sapena, R.; Chermat, F.; Dimicoli-Salazar, S.; Fenaux, P. Journal: Leukemia research Issue: Volume 108(2021)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗